Skip to main content
AIMD
NASDAQ Life Sciences

Director Tsai Chun-Jung Awarded $531K in Equity, Significantly Increasing Stake

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.97
Mkt Cap
$14.314M
52W Low
$1.26
52W High
$4.5
52W Position info
56% above low
Off High info
56% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

AIMD sits 56% above its 52-week low of $1.26 on light trading volume (0.2× avg).

Summary

Director Tsai Chun-Jung received a substantial equity award valued at $531,300, increasing direct holdings by 660,000 shares and aligning interests with shareholders.


Key Events · Ownership and Investor Activity · AIMD

  • Significant Equity Award

    Director Tsai Chun-Jung was granted 660,000 shares of common stock as an award, valued at $531,300, on April 15, 2026.

  • Increased Insider Ownership

    This award, combined with a derivative conversion, significantly increases the director's direct holdings in Ainos, Inc., aligning their interests with shareholders.

  • Part of Broader Equity Grants

    This transaction is part of a series of substantial equity grants to multiple officers and directors reported on the same day, indicating a strategic move to incentivize key personnel.


Analysis · AIMD · Life Sciences

This Form 4 reports a significant equity award to Director Tsai Chun-Jung, valued at $531,300. The award of 660,000 shares, along with a conversion of 330,000 derivative shares, substantially increases the director's direct ownership in Ainos, Inc. This event, occurring concurrently with other significant equity grants to officers and directors, suggests a concerted effort to incentivize management and align their interests with the company's performance, especially given the company's previously disclosed "going concern" issues. While not an open-market purchase, such a large equity grant for a nano-cap company is a material event, demonstrating a commitment to retaining and motivating key personnel.

At the time of this filing, AIMD was trading at $1.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3M. The 52-week trading range was $1.26 to $4.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIMD - Latest Insights

AIMD
Jul 24, 2026, 12:16 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.30 info
Change: Low Volume info
Market Cap: $11.082M info
AIMD
Jul 10, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.89
Real-time Price: $1.30 info
Change: Low Volume info
Market Cap: $11.082M info
AIMD
May 20, 2026, 8:00 AM EDT
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $1.60
Real-time Price: $1.30 info
Change: Low Volume info
Market Cap: $11.082M info
AIMD
May 13, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.85
Real-time Price: $1.30 info
Change: Low Volume info
Market Cap: $11.082M info
AIMD
May 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.30 info
Change: Low Volume info
Market Cap: $11.082M info